<table>
<thead>
<tr>
<th>COVID-19</th>
<th>hhs.gov COVID-19 Vaccine</th>
<th>lagevrio</th>
<th>molnupiravir</th>
<th>remdesivir</th>
</tr>
</thead>
<tbody>
<tr>
<td>Evusheld</td>
<td>Bebtelovimab</td>
<td>Lagevrio: (molnupiravir)</td>
<td>Paxlovid:</td>
<td>VEKLURY (remdesivir)</td>
</tr>
</tbody>
</table>

**Lagevrio:**

- **Purpose:** Treatment of COVID-19 in adults 12 years of age and older who are at high risk of severe illness from COVID-19 due to a known exposure to SARS-CoV-2 (COVID-19) within 5 days of symptom onset.

**Paxlovid:**

- **Purpose:** Treatment of COVID-19 in adults 12 years of age and older who are at high risk of severe illness from COVID-19 due to a known exposure to SARS-CoV-2 (COVID-19) within 5 days of symptom onset.

**Remdesivir:**

- **Purpose:** Treatment of COVID-19 in adults 12 years of age and older who are at high risk of severe illness from COVID-19 due to a known exposure to SARS-CoV-2 (COVID-19) within 5 days of symptom onset.

**Lagevrio:**

- **Purpose:** Treatment of COVID-19 in adults 12 years of age and older who are at high risk of severe illness from COVID-19 due to a known exposure to SARS-CoV-2 (COVID-19) within 5 days of symptom onset.

**Paxlovid:**

- **Purpose:** Treatment of COVID-19 in adults 12 years of age and older who are at high risk of severe illness from COVID-19 due to a known exposure to SARS-CoV-2 (COVID-19) within 5 days of symptom onset.

**Remdesivir:**

- **Purpose:** Treatment of COVID-19 in adults 12 years of age and older who are at high risk of severe illness from COVID-19 due to a known exposure to SARS-CoV-2 (COVID-19) within 5 days of symptom onset.